Indeed, ABT-263, a senolytic compound targeting Bcl-2 anti-apoptotic proteins, killed gemcitabine-resistant and senescent-like pancreatic cancer cells in vitro and reduced pancreatic tumor volume when administered in combination with gemcitabine in mice (Fig. 7b). Here, BCL2 is linked to pancreatic neoplasm.